» Articles » PMID: 30778048

PBK, Targeted by EVI1, Promotes Metastasis and Confers Cisplatin Resistance Through Inducing Autophagy in High-grade Serous Ovarian Carcinoma

Overview
Journal Cell Death Dis
Date 2019 Feb 20
PMID 30778048
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

High-grade serous ovarian carcinoma (HGSOC) is the most lethal type of gynecologic malignancy. Chemoresistance is the main reason for the poor prognosis of HGSOC. PDZ-binding kinase (PBK) promotes the malignant progression of various carcinomas. However, the roles and clinical significance of PBK in HGSOC remain unclear. Here, we reported that PBK was overexpressed in HGSOC tissues and cell lines. High PBK expression was associated with a poor prognosis, metastasis, and cisplatin resistance of HGSOC. Overexpression of PBK promoted autophagy and enhanced cisplatin resistance via the ERK/mTOR signaling pathway. Further study showed that inhibition of autophagy by chloroquine or bafilomycin A1 reversed PBK-induced cisplatin resistance. Overexpression of PBK decreased ovarian cancer responsiveness to cisplatin treatment through inducing autophagy in vivo. We also demonstrated that the PBK inhibitor OTS514 augmented the growth inhibition effect of cisplatin in vitro and in vivo. Moreover, ecotropic viral integration site-1 (EVI1) could regulate PBK expression through directly targeting the PBK promoter region. In conclusion, high PBK expression was correlated with a poor prognosis, metastasis, and cisplatin resistance through promoting autophagy in HGSOC. PBK might be a promising target for the early diagnosis and individual treatment of ovarian cancer.

Citing Articles

Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.


Regulation of ovarian cancer by protein post-translational modifications.

Zhu Q, Zhou H, Xie F Front Oncol. 2024; 14:1437953.

PMID: 39678497 PMC: 11638062. DOI: 10.3389/fonc.2024.1437953.


Unraveling the role of PBK in glioblastoma: from molecular mechanisms to therapeutic targets.

Zhang Y, Luan M Ann Med Surg (Lond). 2024; 86(12):7147-7154.

PMID: 39649886 PMC: 11623866. DOI: 10.1097/MS9.0000000000002708.


Establishment and validation of the prognostic risk model based on the anoikis-related genes in esophageal squamous cell carcinoma.

Cao S, Li M, Cui Z, Li Y, Niu W, Zhu W Ann Med. 2024; 56(1):2418338.

PMID: 39444152 PMC: 11504171. DOI: 10.1080/07853890.2024.2418338.


MECOM Locus classical transcript isoforms affect tumor immune microenvironment and different targets in ovarian cancer.

Lan N, Bai S, Chen M, Wang X, Feng Z, Gao Y J Ovarian Res. 2024; 17(1):207.

PMID: 39427186 PMC: 11490020. DOI: 10.1186/s13048-024-01522-0.


References
1.
Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

2.
Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I . Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005; 169(3):425-34. PMC: 2171928. DOI: 10.1083/jcb.200412022. View

3.
Brooks D, Woodward S, Thompson F, Dos Santos B, Russell M, Yang J . Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996; 74(10):1518-25. PMC: 2074868. DOI: 10.1038/bjc.1996.583. View

4.
Ichimura Y, Kirisako T, Takao T, Satomi Y, Shimonishi Y, Ishihara N . A ubiquitin-like system mediates protein lipidation. Nature. 2000; 408(6811):488-92. DOI: 10.1038/35044114. View

5.
Christie E, Bowtell D . Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii13-viii15. DOI: 10.1093/annonc/mdx446. View